Targeted Approaches to CMV Management: Alleviating the Patient Burden from Prevention to Refractory Disease
Program Overview
Cytomegalovirus (CMV) can be a life-altering reality for patients after solid organ transplant (SOT). Limited antivirals and rising resistance make treatment a challenge. Join Drs. Deepali Kumar and Raymund R. Razonable as they share practical, evidence-based strategies to tackle the most common serious infectious complication after SOT. The faculty will be joined by a patient who will speak directly about how her transplant journey was complicated by CMV and what it means for her to navigate this challenging infection on her path towards healing.
Infectious disease, transplantation, and internal medicine clinicians
Educational Objectives
Upon completion of this activity, participants should be better able to:
Employ updated guidelines in the antiviral prophylaxis and initial management of cytomegalovirus (CMV) in solid organ transplant (SOT) patients
Create treatment strategies for refractory or resistant CMV in SOT recipients that integrate the latest guidelines
Manage adverse events related to CMV antivirals
Activity Faculty
Deepali Kumar, MD, MSc, FRCPC, FAST
Professor, Department of Medicine
University of Toronto Program Medical Director, Ajmera Transplant Program
University Health Network Director, University of Toronto Transplant Institute
Toronto, ON, Canada
Raymund R. Razonable, MD, FIDSA, FAST
Professor, Medicine Associate Chair of Education, Division of Infectious Diseases
Mayo Clinic
Rochester, MN